Camp4 Therapeutics Financials - Benzinga

Camp4 Therapeutics Corp

CAMPNASDAQ

Trade with Public

Trade with Public

$4.20

At close: Aug 27, 5:00 PM EST

$4.45

0.255.95%

After Hours: Aug 25, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Camp4 Therapeutics Financials

Camp4 Therapeutics (CAMP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share

Benzinga Newsdesk

PRO
Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses of $(0.62) per share

Benzinga Newsdesk

Camp4 Therapeutics Earnings Review: Q4 Summary

Benzinga Insights

PRO
Camp4 Therapeutics Q4 EPS $(0.87) Misses $(0.30) Estimate, Sales $348.000K Miss $538.000K Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.30) by 190 percent. This is a 12.99 percent decrease over losses of $(0.77) per share

Benzinga Newsdesk

PRO
Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of $(24.19) per share

Benzinga Newsdesk

PRO
Camp4 Therapeutics Q2 EPS $(0.62) Down From $(0.11) YoY, Sales $1.497M Down From $61.714M YoY

Benzinga Newsdesk